Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2016

Bone Therapeutics announces H1 results for 2016

  • Read more about Bone Therapeutics announces H1 results for 2016

Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

  • Read more about Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

  • Read more about Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

Transparency notification received from Theodorus II SA

  • Read more about Transparency notification received from Theodorus II SA

Enrico Bastianelli to stand down as CEO of Bone Therapeutics

  • Read more about Enrico Bastianelli to stand down as CEO of Bone Therapeutics

Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

  • Read more about Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

Bone Therapeutics Business Update for Third Quarter 2016

  • Read more about Bone Therapeutics Business Update for Third Quarter 2016

Bone Therapeutics announces its financial calendar for 2017

  • Read more about Bone Therapeutics announces its financial calendar for 2017

Pagination

  • Previous page ‹‹
Subscribe to 2016
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions